Presented at PEGS, Boston, MA, USA
TCRs, antibody TCR-mimetics, CARs can provide significant advantages over traditional mAb approaches for the treatment of cancer. However, as highly engineered entities, they pose new design, cloning, expression, purification, and analytics challenges. Our workflow platform, employed by top biopharma companies, enables the automation, engineering, production, and testing of large panels of these candidate therapeutic molecules. We demonstrate the platform’s high-throughput capability when handling novel molecule-specific designs and its built-in tools for developability and manufacturability assessments.